Company news

Indaptus Therapeutics, Inc. (NASDAQ:INDP) news

Indaptus Therapeutics, Inc. news releases on 6ix. Latest, Aug 13, 2026: Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides…

Indaptus Therapeutics, Inc. (NASDAQ:INDP) news

Press releases & updates

Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Indaptus Therapeutics Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit

Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Indaptus Therapeutics Provides Clinical Update

Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference

Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants

Indaptus Therapeutics Announces Reverse Stock Split

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations

Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data

Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses

Indaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement

Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20

Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting

Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20

Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer

Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform

Indaptus Therapeutics Receives Brazilian Patent Allowance for Decoy Platform

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors